Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Total Current Liabilities data on file, last reported at $17.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $17.9 million, up 90.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.9 million (up 90.74% YoY), and the FY2025 annual result was $19.0 million, up 117.28% from the prior year.
• Total Current Liabilities retreated to $17.9 million in Q1 2026 per RAPP's latest filing, from $19.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $19.0 million in Q4 2025 and troughed at $7.1 million in Q3 2024.
• A 4-year average of $11.7 million and a median of $9.4 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities decreased 0.41% in 2024, then surged 117.28% in 2025.
• A 4-year view of Total Current Liabilities shows it stood at $8.8 million in 2023, then retreated by 0.41% to $8.8 million in 2024, then surged by 117.28% to $19.0 million in 2025, then decreased by 6.05% to $17.9 million in 2026.
• Business Quant data shows RAPP's Total Current Liabilities at $17.9 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.